Accelerated Pharma, which is developing a platinum-based chemotherapy optimized by genomic screening, announced terms for its IPO on Tuesday.
The Westport, CT-based company plans to raise $17 million by offering 1.9 million shares at a price range of $8 to $10. At the midpoint of the proposed range, Accelerated Pharma would command a fully diluted market value of $93 million.
The Westport, CT-based company was founded in 2014 and plans to list on the Nasdaq under the symbol ACCP. Accelerated Pharma filed confidentially on March 29, 2016. Rodman & Renshaw and Maxim Group LLC are the joint bookrunners on the deal. IPO timing was not disclosed.
